TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Reynolds risk assessment score for cardiovascular disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean IOP readings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of apneas
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Time below 40% V̇E-baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: V̇E% during the procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Serum morning levels of cortisol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Reduction in synovial thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Reduction in synovial vascularity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Decrease in power Doppler area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: frequency of correct diagnosis for dengue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: prescription of antibiotics
Endpoint domain: Adverse events/effects
Primary endpoint: patients' costs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Health-related quality of life (EQ-5D)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: reduction of right pelvic pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduction of left lower quadrant pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SAQ score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Action potential duration at 90% repolarization (APD90)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Effective refractory period (ERP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction in level of problematic grief
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage at clinical levels of problematic grief
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Reduction in Social Detachment/Insecurity scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: β-cell secretory capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: incretin hormone secretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Comparative safety and efficacy of Plasma-Lyte 148
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Failure to completely remove polyps
Endpoint domain: Adverse events/effects
Primary endpoint: Procedure acceptability
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean postoperative paracetamol consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall average operative cost
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: poorer outcome at the end of treatment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Rate of mid-term re-interventions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: 24h proteinuria decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: BLA responses to facial expressions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Defibrillation rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in serum potassium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in serum albumin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Tenofovir concentration in CVF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Protection against HIV infection
Endpoint domain: Mortality/survival
Primary endpoint: PD-related fatigue
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Parents' perspectives on trial participation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: hearing recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: risk knowledge score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Hand function improvement (FIHOA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall analgesic efficacy (TOPAR8)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall analgesic efficacy (TOPAR12)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall agreement in major stroke types
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Agreement in assessment of stroke severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Certainty of diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median years of life gained
Endpoint domain: Mortality/survival
Primary endpoint: Median time before first cardiovascular event
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: User friendliness of the microdebrider
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Estimated blood loss during surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Objective measurements of pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physiologic stress
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: treatment failure rate by day 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: treatment failure or relapse by day 14
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of EHD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Social Functioning improvement
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Objective energy expenditure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 8-year actuarial rates of second solid primaries
Endpoint domain: Mortality/survival
Primary endpoint: incidence of secondary acute myeloid leukemias (AML)
Endpoint domain: Adverse events/effects
Primary endpoint: Plasma glucose response to glucagon challenge
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Endogenous glucose production (EGP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Insulin-mediated glucose disposal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Fatigue levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nausea/vomiting reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximum FMD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: IMT progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of recurrent venous thromboembolism
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of post-thrombotic syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Incidence of leg ulcers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Concern about developing CRC
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Motivation to reduce CRC risk
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Confidence in behavior change efforts
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Major cardiac-related events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction in deaths after breast cancer
Endpoint domain: Mortality/survival
Primary endpoint: Geometric mean titer (GMT) of anti-F1 antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Geometric mean fold increase (GMFI) of anti-F1 antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Seroconversion rate of anti-rV antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: mean skin perfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Composite of major or clinically relevant minor bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: Changes of the spastic degree
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Activity of metacarpophalangeal articulations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: cumulative primary patency at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Systolic blood pressure improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Increase in disease-related knowledge
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Patient satisfaction with pharmacy staff
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Improvement in ISCmale score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Skin response to sodium lauryl sulfate (SLS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Mean exercise time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Cerebral Blood Flow (CBF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Bone mineral density at lumbar spine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MAS grade
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sleep interference
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: incidence of neuropathic pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: patient-ventilator asynchrony events per hour of sleep
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sleep fragmentation events per hour
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage of REM sleep
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IUGR rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: mfERG values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: OCT thickness measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: OSS improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: duration of sickness absence
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Pain score upon injection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: self-perceived risk of falling
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: confidence to engage in self-protective strategies
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: motivation to engage in self-protective strategies
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Reduction of total fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction of abdominal fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Increment of lean body mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mutations in the thrombomodulin gene
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: angiotensin I levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Number of Uncertain Diagnoses (NUD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite indices of bone strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IPSS score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Recurrence-free survival rates
Endpoint domain: Mortality/survival
Primary endpoint: Number of traumatic injuries
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of moderate and major injuries
Endpoint domain: Adverse events/effects
Primary endpoint: Treatment-related adverse events (TRAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: NICU death rates
Endpoint domain: Mortality/survival
Primary endpoint: application time with gel
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Need for postoperative analgesic use
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Early postoperative complication rates
Endpoint domain: Adverse events/effects
Primary endpoint: daily physical activity (steps/day)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: aerobic capacity (oxygen uptake at the first ventilatory threshold)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of stigma
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: 11β‐HSD1 enzyme inhibition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Fall rate per person
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median percentage of PASI decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median number of sessions needed for clearance
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Median cumulative doses of UVA
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Levels of psoriasin in nasal lavage fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: AUC(0, infinity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Improvement in swollen joint counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in tender joint counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CD4+ T cell depletion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: training impact
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: reductions in mean difference scores on PHQ9
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reductions in mean difference scores on GAD7
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean vertical gaps
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fracture resistance values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: relative cerebral blood volume (rCBV) change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of water samples with no detectable thermotolerant coliform bacteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Mean sensory level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Student confidence in their role during placement
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Student anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Timeframe to transition from classroom to RACF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Weight loss of 5% or more
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Increase in fitness level by 2 points or greater
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjective Global Assessment improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Memory function improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Visuospatial abilities improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Cortisol plasma levels increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: early adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Cigarettes Per Day (CPD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relative peak heart rate increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Heart rate recovery time improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: time to (re)hospitalization
Endpoint domain: Mortality/survival
Primary endpoint: Emotional status improvement
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: mean strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: local muscle endurance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean perceived exertion
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Total effective rate of IM and AH
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time spent by doctors and nurses
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Ability to look after themselves
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: VLDL cholesterol reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cholesterol synthesis inhibition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Success rate of extracorporeal shock wave therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: informed choice
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: adequate risk knowledge
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Bone Mineral Content (BMC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Lactose tolerance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of life improvement
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Quality of life improvement
Endpoint domain: Life impact
Endpoint subdomain: General health
Primary endpoint: Quality of life improvement
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: week 52 abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AO or AV performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Endothelial function by brachial flow‐mediated dilation (FMD%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Cardiac index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oxygen delivery index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: breast-feeding rate at hospital discharge
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: breast-feeding rate at 2-week clinic visit
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: overall speech recognition improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: WBGPx activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PEROXs levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Removal of superficial smear layer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients not receiving donor blood products
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Total nasal airflow
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiovascular events during 3-year follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: post-tonsillectomy pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: return to a regular solid diet
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: cardio-metabolic status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of required intravitreal injections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes